



HAL
open science

Acute respiratory infection due to: current status of diagnostic methods

K. Loens, H. Goossens, M. Ieven

► **To cite this version:**

K. Loens, H. Goossens, M. Ieven. Acute respiratory infection due to: current status of diagnostic methods. *European Journal of Clinical Microbiology and Infectious Diseases*, 2010, 29 (9), pp.1055-1069. 10.1007/s10096-010-0975-2 . hal-00598271

HAL Id: hal-00598271

<https://hal.science/hal-00598271>

Submitted on 6 Jun 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Editorial Manager(tm) for European Journal of Clinical Microbiology & Infectious
Diseases
Manuscript Draft

Manuscript Number: EJCMIID-D-10-00199R1

Title: Acute respiratory infection due to *Mycoplasma pneumoniae*: Current status of diagnostic methods

Article Type: Review

Keywords: *Mycoplasma pneumoniae*; respiratory infections; PCR; serology; culture; epidemiology

Corresponding Author: Dr. K. Loens, PhD

Corresponding Author's Institution: University of Antwerp

First Author: K. Loens, PhD

Order of Authors: K. Loens, PhD; Herman Goossens; Margareta Ieven

Abstract: Because of the absence of well-standardized both in-house and FDA-approved commercially available diagnostic tests, reliable diagnosis of respiratory infection due to *Mycoplasma pneumoniae* remains difficult. In addition no formal external quality assessment schemes which would allow to conclude about the performance of *M. pneumoniae* diagnostic tests exist. Because of the absence of well-standardized and commercially available diagnostic tests, reliable diagnosis of respiratory infection due to *Mycoplasma pneumoniae* and investigation of its role in infectious diseases remains difficult since no formal external quality assessment schemes for *M. pneumoniae* serology or molecular detection exist. In this review, the current state of knowledge of *M. pneumoniae*-associated respiratory infections in the context of epidemiological studies published during the past 5 years is discussed, with particular emphasis on the diagnostic strategies used and their impact on results. The role of *M. pneumoniae* as a cause of respiratory tract infections (RTIs) differs from study to study due to geographical and epidemiological differences as well as to the application of different diagnostic techniques and criteria used.

Reply to the reviewers EJCMID-D-10-00199:

Reviewer 1:

General comments: NOG STERK IN TE KORTEN

“The paper could be improved by the inclusion of a short list practical guidelines on how a novel diagnostic test should be validated and evaluated”: The following lines are added to the manuscript: “The following standards should be followed by all laboratories when validating new tests for the detection of *M. pneumoniae*: (i) having the ability to apply a 2nd PCR at another target to at least some cases in, epidemic situations, (ii) performing proficiency testing regularly in a blind fashion to ensure proper test and personnel performance, and (iii) incorporating hierarchical acceptance criteria monitoring for test failures, including positive and negative controls, re-evaluating multiple consecutive positive specimens, and confirming that positive specimens were collected from persons meeting the clinical case definition. Furthermore, multicenter studies that use a large and geographically diverse repertoire of clinical specimens and compare data from >2 centers independently are likely to provide important insights into the performance of new assays.”

Specific comments:

1. Line 10: The first sentence should be rephrased and clarified. It may now be read as such:
 - (i) Reliable diagnosis and investigation of the role of *M. pneumoniae* remains difficult due to:
 - i. the absence of well-standardized tests, and
 - ii. the absence of formal external quality assessment schemes.'

“Because of the absence of well-standardized and commercially available diagnostic tests, reliable diagnosis of respiratory infection due to *Mycoplasma pneumoniae* and investigation of its role in infectious diseases remains difficult since no formal external quality assessment schemes for *M. pneumoniae* serology or molecular detection exist” is changed into: “Because of the absence of well-standardized both in-house and FDA-approved commercially available diagnostic tests, reliable diagnosis of respiratory infection due to *Mycoplasma pneumoniae* remains difficult. In addition no formal external quality assessment schemes which would allow to conclude about the performance of *M. pneumoniae* diagnostic tests exist”.
2. Line 17: The manuscript was rechecked for RTI and RTIs.
3. Line 20: Define NAATs: “nucleic acid amplification techniques”, done as requested by the reviewer
4. Line 22: Not specified in instructions to the authors
5. Line 22-23: changed into: Studies comparing different methods
6. Lines 40-41: rephrased as also suggested by reviewer 2.
7. Line 51: Define LRTI: “Lower Respiratory Tract Infection”, done as requested by the reviewer
8. Line 57: Change 66,7% into 66.7%, done as requested by the reviewer

9. Line 235: CARDQ should be CARDS: done as requested by the reviewer
10. Line 256-257: rephrased as requested by the reviewer
11. Line 265: define QCMD: “Quality Control for Molecular Diagnostics”, done as suggested by the reviewer
12. Line 266: atypical bacteria: please correct: “atypical”, done as requested by the reviewer
13. Line 275: define MX-NAATs: “multiplex nucleic acid amplification techniques”, done as requested by the reviewer
14. Lines 282-284: What does 5.10^2 color changing units per reaction tube for *M. pneumoniae* mean? CCU: a unit to express the quantity of *M. pneumoniae*.
15. Lines 295-296: 'A comparative analysis [...] of the ResPlex I assay (Table 4) and real-time single PCR assays demonstrated that the MX-PCR assay is 10-fold less sensitive'. Does MX-PCR assay refer to the ResPlex assay? This is ambiguous here; please rephrase. Indeed. Done as suggested by the reviewer.
16. Line 297: define NP: “nasopharyngeal”, defined as requested by the reviewer
17. Lines 315-318: The sentence “Automated nucleic acid extraction systems with high flexibilities in type and numbers of samples to be handled, and with a wide range of sample input and elution volumes and short turn around time will provide another opportunity to maximally apply amplification techniques to clinical services.” should be rephrased (and shortened). It is too long. Changed into “Automated nucleic acid extraction systems with high flexibilities in type and numbers of samples to be handled, and with a wide range of sample input and elution volumes and short turn around time will improve the application of NAATs to clinical services.”
18. Lines 354-end: see general comment above
19. Line 355: To which 'quality control studies' do the authors refer? The references were added.
20. Line 357: deleted as requested by the reviewer
21. Line 364: The authors state that 'proficiency panels for the detection of *M. pneumoniae* are not readily available', whereas in lines 263-265 they refer to a 'pilot panel for molecular diagnosis of *M. pneumoniae*' produced by QCMD. Please explain. Until now, only 2 EQA studies have been organized in Belgium. QCMD organized 1 in the spring of 2008 and another one in 2009. These were the first EQAs that were open to all laboratories performing NAATs which are interested to evaluate their tests on a voluntary basis.
22. Lines 373-375: deleted as requested by the reviewer
23. All table titles: change *Mycoplasma pneumoniae* into *M. pneumoniae*: done as requested by the reviewer
24. Tables 1 and 2: define “.” In the final column: “...: no major methodological problems identified”, done as requested by the reviewer
25. Table 2: [64] 2007: OK, data added
26. Table 2: NS not defined: “not specified,” done as requested by the reviewer

27. Table 3: change P1-gene into P1 gene: done as requested by the reviewer
28. Table 3: Define product size and “.”: done as requested by the reviewer
29. Table 3 and 4: write full bacterial genus names: done as requested by the reviewer
30. Table 3: study [77] 2008: deleted
31. Table 4: define product size and NS and NPAs: done as requested by the reviewer
32. Table 4: study [33] 2007: correct influenza a and B: done as requested by the reviewer
33. Table 4: clarify reanalysis discrepant results in study [25] 2008: Done as requested by the reviewer

Reviewer 2:

Specific comments

1. Page 3, lines 5-6: delete “to standardize diagnostic efforts”: done as requested by the reviewer
2. Page 9, lines 32-33 unclear: the following sentence “Two commercial (RepMp1 (artus) and Venor Mp-QP *M. pneumoniae* kit (Minerva biolabs)) and 3 real-time in house PCR assays for the detection of *M. pneumoniae* on the LightCycler (Roche) were compared under standardized conditions by Dumke et al. [11]” was changed into “Dumke et al. [11] compared under standardized conditions the performance of two commercial PCR assays (Artus RepMp1 (QIAGEN GmbH, Hilden, Germany), and the Venor Mp-QP *M. pneumoniae* kit (Minerva Biolabs GmbH, Berlin, Germany) and 3 in-house PCR for the detection of *M. pneumoniae* on the LightCycler (Roche Diagnostics GmbH, Mannheim, Germany).
3. Line 58: replace “to be” with “were”: done as suggested by the reviewer
4. Page 10, line 17 description QCMD results: The following was added to the text: “An external quality assessment (EQA) panel consisting of a total of 13 samples in broncho alveolar lavage (BAL) or transport medium were prepared to assess the proficiency of laboratories in the correct detection of *Chlamydophila pneumoniae* and *Mycoplasma pneumoniae* by NAATs (6 samples containing various concentrations (4.9-490 inclusion forming units (IFU)/ml) of *C. pneumoniae*, 5 samples containing various concentrations (20-5000 color changing units (CCU)/ml) of *M. pneumoniae* and 2 samples negative for both) [34]. 79 laboratories from 18 countries participated in this EQA study. 67 datasets were obtained for *M. pneumoniae* (n=5 conventional commercial, n= 10 conventional in-house, n=4 real-time commercial, n= 46 real-time in-house, n=2 strand displacement amplification (SDA)). For the total panel, correct results per sample varied between 53.7% and 95.5% for *M. pneumoniae*.
5. Line 30: “monoplex” instead of “mono” done as requested by the reviewer
6. Line 36: see remark 13 reviewer 1
7. Page 11, line 15: monoplex” instead of “mono” done as requested by the reviewer
8. Page 12: culture after serology: done as requested by the reviewer

9. Line 42: add “in Europe”: done as requested by the reviewer
10. Line 47 short description of these PCR assays: The following lines are added to the manuscript: “Both assays target the V-domain of the 23S rRNA gene; the presence of point mutations in the amplicons is detected by using RFLP [45] or high resolution melt curve analysis [95].
11. Page 13, line 50: see remark 22 reviewer 1
12. Table 1: change “problem” in “problems”: done as requested by the reviewers
13. Table 1 and 2: see also remark 24 reviewer 1
14. Table 3 and 4: The last column in both tables was added to show that all tests were validated using a different approach to test the specificity (different organisms) and the (analytical) sensitivity of the assay. Therefore, we prefer to keep this last column.
15. Table 3 and 4: see also remark 28 reviewer 1
16. Affiliation of commercial kits/assays: done as requested by the reviewer

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acute respiratory infection due to *Mycoplasma pneumoniae*: Current status of diagnostic methods

Loens K.*, H. Goossens, and M. Ieven

5 Submitted to: The European Journal of Clinical Microbiology and Infectious Diseases

* Correspondent footnote: Department of Microbiology, Vaccine and Infectious Disease Institute (VIDI), University of Antwerp, Antwerp, Belgium. Phone: +32-3-265-27-51. Fax: +32-3-265-27-52. E-mail: Katherine.loens@ua.ac.be

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Formatted: English (U.S.)

~~Because of the absence of well-standardized both in-house and FDA-approved commercially available diagnostic tests, reliable diagnosis of respiratory infection due to *Mycoplasma pneumoniae* remains difficult. In addition no formal external quality assessment schemes which would allow to conclude about the performance of *M. pneumoniae* diagnostic tests exist.~~

~~Because of the absence of well-standardized and commercially available diagnostic tests, reliable diagnosis of respiratory infection due to *Mycoplasma pneumoniae* and investigation of its role in infectious diseases remains difficult since no formal external quality assessment schemes for *M. pneumoniae* serology or molecular detection exist.~~ In this review, the current state of knowledge of *M. pneumoniae*-associated respiratory infections in the context of epidemiological studies published during the past 5 years is discussed, with particular emphasis on the diagnostic strategies used and their impact on results. The role of *M. pneumoniae* as a cause of respiratory tract infections (RTIs) differs from study to study due to geographical and epidemiological differences as well as to the application of different diagnostic techniques and criteria used.

In 2003, we already stated that proper validation and standardization of nucleic acid amplification techniques (NAATs) are often lacking, and that the different methods used must be compared to define the most sensitive and specific tests [40]. This is similar for existing serological tests and other new diagnostic tests as well. ~~These s~~Studies comparing different methods still remain to be undertaken and will be critically important for development of a standardized test for clinical laboratories.

Mycoplasma pneumoniae belongs to the class of the *Mollicutes* and has been associated with a wide variety of acute and chronic diseases. RTIs with *M. pneumoniae* occur worldwide and in all age groups.

Serological methods, in particular such as the complement fixation test (CFT) and EIAs, are most widely used to diagnose a *M. pneumoniae* infection. The application of PCR is more and more accepted as a rapid diagnostic test since culture is too slow and too insensitive to be therapeutically relevant. Only a few of the currently available ~~nucleic acid amplification tests (NAATs)~~ nucleic acid amplification tests (NAATs) have been extensively validated against culture, which remains the reference standard despite its low sensitivity and variable yield, depending on the specimens tested and the isolation protocols used. The sensitivity of NAATs is almost

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

always superior to that of the traditional procedures and they are more and more considered as the “new gold standard”. However, different studies have used not only different diagnostic tools or combinations thereof, but also different diagnostic criteria for making a diagnosis of an infection thereby making comparison between studies difficult. Most importantly, lack of standardization has resulted in a wide variation of interlaboratory test performance, even when using the same test and criteria [37]. In an effort to standardize diagnostic assays for *C. pneumoniae* ~~an effort to standardize diagnostic efforts~~ recommendations have been published by the US Centers for Disease Control and Prevention (CDC) and the Canadian Laboratory Center for Disease Control in 2001 [10]. However, no such recommendations exist for standardizing the diagnostic approach for *M. pneumoniae*. The epidemiology of *M. pneumoniae*-associated respiratory infections in studies performed all over the world for the purpose of examining the current state of knowledge of *M. pneumoniae* diagnostics since the publication of the 2003 minireview [40] was reviewed.

Epidemiology of Respiratory Infection Due to *M. pneumoniae*

Varying with the population studied and diagnostic methods used, in studies published during the 1990s, in 6 - >30% of lower respiratory tract infections (LRTI) an association was found with *M. pneumoniae* [14,56,87]. Over 50 additional studies have been published about *M. pneumoniae*-associated LRTI since 2003. Data from selected studies chosen to represent different populations from around the world are summarized in tables 1 and 2. As shown in these tables, the proportion of LRTI in children and adults, including community-acquired pneumonia, associated with *M. pneumoniae* infection during the past 5 years has ranged from 0% to 66.7% [58,63], varying with age and the geographic location of the population examined and the diagnostic methods used. In a lot of studies, the diagnosis of *M. pneumoniae* was based on serology alone [8,27,58,75]; some used a PCR assay alone [19,32,63] or at least 1 serological test and a PCR assay [15,43,72,76,80,86,96], only a limited number of studies used culture in combination with a serological test and/or PCR assay [23,36,49,65,73] and 3 studies applied 2 different PCR assays [4,44,60]. Furthermore, there was a high degree of heterogeneity from study to study in the serological methods and criteria used. These are not necessarily interchangeable. In some studies, no data were presented on the type of assay and the

1
2
3
4
5
6
7
8
9
10 criteria used, thereby making it difficult, if not impossible, to compare results from one
11 study to another.
12

13 One example is a prospective study of the incidence and etiology of community-acquired
14 pneumonia in hospitalized adult patients [47] published in 1999. The researchers used
75 serological methods and PCR for the diagnosis of an *M. pneumoniae* infection. The
16 following serological criteria were used: a fourfold rise or seroconversion in IgG and/or a
17 IgM positive titer for *M. pneumoniae*. Fourteen percent of the patients were thought to
18 have serological evidence of *M. pneumoniae* infection, but no information was provided
19 on the serological method used. Furthermore, the study had no control subjects, and
20 because of their absence, the significance of the reported seroprevalence of the patient
21 group cannot be known. Background rates of seropositivity can be very high in some
22 adult populations, ranging from 36% to 93% for IgG and ranging from 0%-51% for IgM
23 depending on the assay used [1].
24
25
26
27
28

29 Another example is a study of Oosterheert et al. [63]. In a randomized controlled trial,
30 nasopharyngeal and oropharyngeal swab specimens from patients admitted for antibiotic
31 treatment of LRTI were evaluated by means of real-time PCR for respiratory viruses and
32 atypical pathogens, as well as by conventional diagnostic procedures for virus detection.
33 No details on the real-time PCR were given although no *M. pneumoniae* positive patients
34 results were identified. No other methods were used in this study to confirm the negative
35 results.
90

36 In general, in more recent studies using PCR assays, lower rates of *M. pneumoniae*-
37 associated LRTI have been reported than in studies using serological testing (Table 1 and
38 2). During a community outbreak of *M. pneumoniae*, Nilsson et al. [60] compared
39 seminested and real-time PCR of oropharyngeal swabs with serology for diagnosis of *M.*
40 *pneumoniae* infections at different time points after onset of disease. *M. pneumoniae* was
41 diagnosed in 48/164 patients with a respiratory tract infection. Fortyfive (29%) were PCR
42 positive whereas a significant rise in IgG titre or IgM antibodies was detected in 44/154
43 (27%) subjects. Although the authors found that persistence of *M. pneumoniae* DNA in
44 the throat was common and could be present for up to 7 weeks after onset of disease, they
45 concluded that PCR was superior to serology for diagnosis of a *M. pneumoniae* infection
46 during the early phase of infection. When examining 73 children with RTIs for *M.*
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

pneumoniae by real-time PCR, and 2 serological assays (a passive agglutination test and the Immunocard assay), Otomo et al. [64] confirmed the results of Nilsson et al. [60].
105 They found a sensitivity of 100% and 33.3% and a specificity of 100% and 82.1% for PCR and the Immunocard assay, respectively. According to the authors, real-time PCR or a related molecular assay is suitable for rapid diagnosis as a first screening test. These data confirmed the lack of correlation of serological methods with culture and/or PCR assays reported in earlier studies [40].

110 The epidemiological data emerging from pediatric studies have revealed similar inconsistencies of the methods and criteria used to make a diagnosis of an acute *M. pneumoniae* infection (Table 2). Examples include the use of single IgG titers by some studies (Table 2). A more specific example is a small uncontrolled pediatric study in Turkey [76] collecting nasopharyngeal samples for PCR detection of *M. pneumoniae*
115 DNA and blood for serology on the first admission to the hospital. However, they did not specify the PCR test applied, and although blood was only collected once (on hospital admission), serological diagnosis was made according to the materials and methods section by demonstrating an increment of IgM greater than 1/10 and a 4-fold increase in IgG with ELISA. No positive case definition was mentioned either. The authors
120 concluded that serological tests were more sensitive and specific than PCR since the false positive ratio for PCR was 16.2%. Another small uncontrolled pediatric study in Dallas, Texas [48], identified *M. pneumoniae* as the cause of infection in 14% of patients with pneumonia. The centre applied an ELISA for serological testing and used a 4-fold increase of IgG or single IgM titers of $\geq 1:10$ as evidence of acute infection. However,
125 they did not specify the proportion of positive results by the different antibody classes and no info on the ELISA was presented.

The true role of *M. pneumoniae* in RTIs remains a challenge given the wide variations of data from studies with equally wide variation of and lack of standardized diagnostic methods.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

130 **Serology**

The serologic measurement of specific antibody responses has limited application for an etiologic diagnosis of a *M. pneumoniae* infection because diagnostic results are only available retrospectively.

135 A great number of antigen preparations have been proposed: whole organisms, protein fractions, glycoprotein fractions, recombinant antigens. Some commercialized assays lack both sensitivity and specificity, emphasizing the need for more validation and quality control [1,61,67,82].

The sensitivity of the serological assays depends on whether the first serum sample is collected early or late after the onset of disease and on the availability of paired sera since 140 for an accurate diagnosis to be made paired serum samples are required with a 4-fold rise in titer appearing after three to four weeks after onset of the disease [16]. In practice however often only one serum sample, from the acute-phase of the illness is available or the two samples are collected within a too short time interval to detect a titer rise. Solitary high IgG titers have no diagnostic meaning for an acute infection since the moment of the 145 seroconversion is unknown and necessarily took place some time before the illness under observation started. Single high titres, for which a cut-off value has to be determined by a local evaluation, are useful only in prevalence studies among population groups.

Since IgM antibodies appear earlier than IgG antibodies the detection of IgM in serum is a widely used approach for the early serologic diagnosis of a *M. pneumoniae* infection, 150 especially in children. It should be realized that IgM antibodies are often not produced in children under 6 months of age, in a proportion of primary infections and during reinfections. A single IgM measurement may detect an acute infection with higher sensitivity if the test is performed after at least 7 days after onset of disease [31]. In some patients, IgM antibodies appear even later [89]. Ozaki et al. [65] found that a single assay 155 using the IgM Immunocard (Meridian Biosciences) had a sensitivity of 31.8% for detection of an acute *M. pneumoniae* infection which increased to 88.6% when paired sera were analyzed from seropositive children with pneumonia. Furthermore, an elevated IgM may persist for months after the acute infection [57]. IgM tests are usually less sensitive and specific than 4-fold changes in antibody titres between paired specimens 160 separated by several weeks [77].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

It has been reported that the detection of IgA-specific antibody seems to be a good indicator of a recent *M. pneumoniae* infection in both children and adults [28,29,93]. On the other hand, when evaluating the Medac IgM, IgG and IgA assay on 159 serum samples from 113 patients with acute RTIs, Narita [59] did not find a significant advantage of detecting IgA in children.

Talkington et al. [82] compared 8 commercial EIAs (2 single-use EIAs and six plate-type EIAs) for detection of specific IgM/IgG antibodies, using paired serum samples from 51 patients with a confirmed *M. pneumoniae* infection and a positive complement fixation test (CFT). Results from acute phase sera ranged from 14% ImmunoWELL IgM positive to 45% positive by Zeus IgG EIA. When both the acute-phase and convalescent phase serum samples were analyzed, positive results ranged from 39% by the ImmunoWELL IgM assay to 88% positive by the Remel IgG-IgM EIA. In their study, the single-use EIAs proved to be more reliable than the plate-type EIAs. Beersma et al. [1] evaluated the sensitivity and specificity of 12 assays for the detection of *M. pneumoniae* IgM and IgG as well as the CFT. Some of the assays had a low sensitivity (Novum and Immunocard IgM) while the best performances in terms of sensitivity and specificity were recorded for ANILab systems (77% and 92% respectively) and the CFT (65% and 97% respectively). Petitjean et al. [67] found similar IgM sensitivities with 4 *M. pneumoniae* tests in children: between 89% and 92% but wide variations in adults: Platelia and BMD 16%, Biotest 50% and Sorin 58%. The specificities of the tests were 100%, 90%, 65% and 25% respectively. The latter two IgM tests can thus not be used for diagnosis. The sensitivities of the IgG tests in children varied between 52% and 78%. The sensitivities for the IgG tests in adults were comparable: between 89% and 92%. When comparing 4 IgM, IgG and IgA-specific EIAs in sera from 504 blood donors and 102 patients with infections not caused by *M. pneumoniae*, Csango et al. [5] reported detection frequencies of IgM in blood donors varying between 2.8% and 16% and in patients between 9.8% and 42.2%. IgA was detected in 22.8%-68.5% of blood donor sera and in 53.8%-100% of patients, illustrating again that the use of some serological kits may lead to a serious overdiagnosis of *M. pneumoniae* infections. Finally, Nir-Paz et al. [61] compared 8 commercially available tests for *M. pneumoniae* using 204 single sera from healthy individuals. The study showed that age was associated with test positivity in healthy individuals, with the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

IgM peaking at primary/secondary school age, and declining thereafter while IgG rose progressively into adulthood. The high IgM positivity in these age groups casts doubt on the suggestion that combining IgM tests with amplification-based tests in the pediatric population might be of benefit [9,87,92]. Inter-assay agreement was poor. The study confirmed that single serum serology is unsuitable for the diagnosis of *M. pneumoniae* infection, and that commercially available tests need further improvement.

In conclusion, serologic tests can never offer an early diagnosis and are therefore rather an epidemiological than a diagnostic tool. The clinical significance of a serologic test, for both IgM and IgG, should be defined by studies of patients with a documented infection and for whom detailed information concerning the time lapses between onset of disease and the collection of the serum specimens are known.

Culture

M. pneumoniae was first recovered on a medium devised by Hayflick in which PPLO agar [55] was supplemented with a fresh yeast extract preparation of Edward [13] and 20% horse serum. However, *M. pneumoniae* grows slowly, cultures may require up to 6 weeks to become positive. Although culture of *M. pneumoniae* is still considered the gold standard, it is seldomly performed as a diagnostic test.

Culture is and will remain essential for further biological and molecular characterization of clinical isolates (incl. antibiotic resistance studies), however, its use as a routine diagnostic tool is suboptimal.

PCR

Over the last 20 years NAATs have become a major tool for the detection of micro-organisms, for diagnostic testing, and for research purposes in the field of infectious diseases. NAATs offer significant sensitivity and speed compared to culture and do not require the presence of viable organisms. Diagnostic testing for micro-organisms based on NAATs has become increasingly complex and the field is changing and expanding rapidly. Thus, a NAAT established 10 years ago and designed with the best information and knowledge available at that time may not necessarily be state-of-the-art today.

Validated commercially available FDA-cleared assays exists only for a limited number of organisms and not for the detection of *M. pneumoniae* in respiratory or other specimens. There are also a number of so-called analyte-specific reagents commercially available.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Besides these standardized kits, the use of NAATs for research purposes kits and in-house developed NAATs has expanded tremendously. The assays range from those that are well validated to those that are not. Carefully reading many of these publications reveals that often little or no information is provided on the validation of the NAATs applied. Yet, these assays are frequently used and cited in the literature.

At the time of the 2003 minireview [40], there were 34 published in-house NAATs for detection of *M. pneumoniae* DNA or RNA. However, validation was primarily analytical; none of these assays were extensively evaluated using clinical specimens from well-defined patient populations from a wide geographic area. Since then, an additional 27 assays have been described (Tables 3 and 4). There is a great variation of the methods used from study to study, including variability of target (P1 gene, 16S rRNA, ATPase gene, *parE* gene, *tuf* gene; monoplex versus multiplex targets) and of NAAT (conventional, nested, and real-time; RNA vs. DNA targets; and PCR and nucleic acid sequence-based amplification technologies) and detection formats (agarose gel electrophoresis, SYBR green, TaqMan probe, hybridization probes, molecular beacons, and microchip electrophoresis). Furthermore, there is no consensus on the optimal respiratory specimen to be used for *M. pneumoniae* detection by nucleic acid amplification tests and culture. Different specimens have been used such as sputum, nasopharyngeal, or oropharyngeal swabs or washes; bronchoalveolar lavage; or pleural fluid). In a review on optimal sampling for the detection of respiratory pathogens, Loens et al. concluded that if sputum is available, it might be the best specimen for *M. pneumoniae* detection by culture and NAATs. A nasopharyngeal swab, nasopharyngeal aspirate or oropharyngeal swab might be the second best option for analysis by NAATs [42].

Interstudy variation is related to the reference diagnostic assay with which the new assay is compared (a serological test, culture, or a pre-existing PCR assay). Due to the lack of conformity between different studies it is very difficult to compare the data from study to study.

Winchell et al. [94] evaluated 3 real-time PCR assays targeting the ATPase gene and newly described ~~CARDQ~~ **CARDS** toxin genes during a *M. pneumoniae* outbreak. A total of 54 respiratory specimens from patients (n=35) and controls (n=19) were tested in

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

triplicate with each PCR assay. The assay targeting the CARDS toxin gene proved to be the most sensitive (lower ct-values) in identifying positive specimens. The analytical sensitivity of this assay was between 1-5 CFU whereas, it was between 5-50 CFU for the other 2 assays. However the authors concluded that the inclusion of a 2nd PCR assay may provide an increased level of confidence for the reporting of results. ~~Two commercial (RepMp1 (artus) and Venor Mp-QP *M. pneumoniae* kit (Minerva biolabs)) and 3 real-time in-house PCR assays for the detection of *M. pneumoniae* on the LightCycler (Roche) were compared under standardized conditions by Dumke et al. [11].~~ compared under standardized conditions the performance of two commercial PCR assays (Artus RepMp1 (QIAGEN GmbH, Hilden, Germany), and the Venor Mp-QP *M. pneumoniae* kit (Minerva Biolabs GmbH, Berlin, Germany) and 3 in-house PCR for the detection of *M. pneumoniae* on the LightCycler (Roche Diagnostics GmbH, Mannheim, Germany). All 5 procedures were able to demonstrate *M. pneumoniae* DNA in a concentration comparable to 1 CFU/μl but the differences in the mean crossing points between the tested procedures (up to 4.6) caused differences of the calculated mean concentration of the genome equivalents by a factor up to 20.

Multicenter studies that use a large and geographically diverse repertoire of clinical specimens and compare data from >2 centers independently are likely to provide important insights into the performance of new assays. To date, only 2 such studies describing multicenter comparisons of the performance of various NAATs for detection of *M. pneumoniae* in respiratory specimens have been published, and both studies revealed significant variations of test performance from laboratory to laboratory [37,85]. Ursi et al. collected a panel of 78 respiratory samples from 43 patients which to ~~be~~ were analyzed in three different Centers for the presence of *M. pneumoniae* DNA by different PCR assays [85]. Nucleic acids were extracted at 1 site and subsequently amplified in 3 centers. Loens et al. [37] used spiked respiratory specimens to compare the performance of several NAATs being used by 18 laboratories each with their own extraction and amplification protocols. Both of these studies revealed significant intercenter discordance of detection rates, using different or even the same tests, despite the fact that the laboratories participating were very experienced with the use of PCR assays. In the spring of 2008, a pilot panel for molecular diagnosis of *M. pneumoniae* was produced by

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

285 Quality Control for Molecular Diagnostics (QCMD). An external quality assessment
(EQA) panel consisting of a total of 13 samples in broncho alveolar lavage (BAL) or
transport medium were prepared to assess the proficiency of laboratories in the correct
detection of *Chlamydomphila pneumoniae* and *Mycoplasma pneumoniae* by NAATs (6
samples containing various concentrations (4.9-490 inclusion forming units (IFU)/ml) of
290 *C. pneumoniae*, 5 samples containing various concentrations (20-5000 color changing
units (CCU)/ml) of *M. pneumoniae* and 2 samples negative for both) [34]. 79 laboratories
from 18 countries participated in this EQA study. 67 datasets were obtained for *M.*
pneumoniae (n=5 conventional commercial, n= 10 conventional in-house, n=4 real-time
commercial, n= 46 real-time in-house, n=2 strand displacement amplification (SDA)).
295 For the total panel, correct results per sample varied between 53.7% and 95.5% for *M.*
pneumoniae.

Respiratory viruses and other so called “atypical bacteria” are all responsible for RTIs that may produce clinically similar manifestations. In order to reduce costs and hands-on-time, multiplex NAATs-nucleic acid amplification techniques (MX-NAATs) have been developed (Table 4). Originally only 2 or 3 organisms were targeted in 1 assay. Currently 300 some assays detect up to 22 targets [30]. However, comparison between mono-plex and multiplex assays has been rarely performed. Findings and conclusions result frequently in contradictory and conflicting data concerning the sensitivity and specificity of the multiplex-MX-NAATs compared to the monoplex NAAT. Owing to the complexity of 305 the variables in a multiplex PCR including different combinations of primer concentrations, magnesium ion concentrations, and annealing temperatures, this is not unexpected. The results of MX-NAATs on proficiency panels [37] seem to confirm that multiplex assays are somewhat less sensitive than monoplex assays but until the number of organisms present in clinical specimens of diseased individuals is known, it is 310 impossible to state whether the degree of sensitivity attained is clinically acceptable.

It has been proposed that industry-produced assays in kit form may enable standardization. The Pneumoplex assay (Prodesse Inc.) (Table 4) was reported to have 100% sensitivity (when the sample contained 5 CFU/ml of *M. pneumoniae*) and 96% specificity, for detection of *M. pneumoniae* in spiked specimens [22]. The sensitivity of 315 the Chlamyge assay (Argene Inc.) (Table 4) was 5.10^{-2} color-changing unitsCCU per

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

reaction tube for *M. pneumoniae* [18]. A cohort of 154 clinical samples from patients with documented respiratory infections was analyzed by the same kit, including 2 samples from patients with *C. pneumoniae* infection, 9 samples from patients with *M. pneumoniae* infection, 19 samples from patients with *Legionella* species infection, and 114 samples that tested negative for the three pathogens. All the positive specimens were correctly detected and identified by the Chlamyge kit, and no false-positive result was observed with the negative samples. The kit was then evaluated in a pediatric prospective study that included 220 endotracheal aspirates, and the results were compared with those obtained by three ~~single-monoplex~~ in-house PCR assays. Six specimens were found to be positive for *M. pneumoniae* by using both strategies. The Chlamyge kit detected two additional samples positive for *M. pneumoniae*. A comparative analysis of the limits of detection of the ResPlex I assay (Table 4) and real-time single PCR assays demonstrated that the ~~MX-PCRResPlex_I~~ assay is 10-fold less sensitive in detecting *M. pneumoniae* [2]. Furthermore, the ResPlex I assay was performed on 49 ~~NP-nasopharyngeal~~ swab specimens known to be positive by real-time PCR for three pathogens (*C. pneumoniae*, *M. pneumoniae*, and *S. pneumoniae*) and detected 50, 59, and 81% of the *C. pneumoniae*-, *M. pneumoniae*-, and *S. pneumoniae*-positive samples, respectively. However, since the calculation of the sensitivities of the industry-produced multiplex assays was mainly dependent on DNA copy number, further evaluation and standardization using an extended number of clinical specimens that may have a low load of the organism are needed.

There is also more and more a trend of adapting commercially available (eg MicroSeq Mycoplasma, Applied Biosystems) or in-house PCR assays for screening cell cultures for the presence of *Mollicutes* to respiratory specimens for the specific or generic detection of *M. pneumoniae* [78,90]. These assays need to be extensively validated in terms of sensitivity and specificity as well before they can be applied to clinical respiratory specimens.

Ideally, a newly proposed NAAT assay should be validated by comparison with a sensitive culture system and at least one validated PCR or another NAAT assay that targets a different gene or a different sequence of the same gene.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Conventional manual nucleic acid extraction for the isolation of pathogen DNA or RNA from clinical samples is the most labor-intensive and critical part in current nucleic acid diagnostic assays. ~~Automated nucleic acid extraction systems with high flexibilities in type and numbers of samples to be handled, and with a wide range of sample input and elution volumes and short turn around time will provide another opportunity to maximally apply amplification techniques to clinical services. Automated nucleic acid extraction systems with high flexibilities in type and numbers of samples to be handled, and with a wide range of sample input and elution volumes and short turn around time will improve the application of NAATs to clinical services.~~ Data from the literature indicate that the sensitivity of a NAAT after nucleic acid extraction with an automated system is similar to or better than the sensitivity after manual nucleic acid extraction. When the easyMAG nucleic acid extractor (bioMérieux) was applied retrospectively to clinical specimens, better amplification results were obtained for *M. pneumoniae* and *C. pneumoniae* detection compared with manual methods such as the Qiagen blood mini kit and the NucliSens miniMAG platform [38,41]. This and other automated nucleic acid extraction instruments need to be further evaluated.

Formatted: English (U.S.)

Culture

~~*M. pneumoniae* was first recovered on a medium devised by Hayflick in which PPL0 agar (54) was supplemented with a fresh yeast extract preparation of Edward (13) and 20% horse serum. However, *M. pneumoniae* grows slowly, cultures may require up to 6 weeks to become positive. Although culture of *M. pneumoniae* is still considered the gold standard, it is seldomly performed as a diagnostic test.~~

~~Culture is and will remain essential for further biological and molecular characterization of clinical isolates (incl. antibiotic resistance studies), however, its use as a routine diagnostic tool is suboptimal.~~

Antibiotic resistance

Since in 2001 a report was published describing the first macrolide-resisant *M. pneumoniae* strain possessing a 23S rRNA gene mutation [62], other reports followed [45,52,53,81]. Although most macrolide-resistant strains were detected in Japan so far, the first macrolide-resistant *M. pneumoniae* strains in Europe were reported recently in France [66]. Since the impact of macrolide resistance on the outcome of the infections is

not clear so far measures need to be taken to identify these strains and PCR assays have been developed to detect some of these mutations [45,95]. Both assays target the V-domain of the 23S rRNA gene; the presence of point mutations in the amplicons is detected by using RFLP [45] or high resolution melt curve analysis [95].

Conclusions and Future Directions

During recent years significant progress has been made in the microbiological diagnosis of *M. pneumoniae* RTIs. Despite these many efforts, much is still unknown about the role of *M. pneumoniae* in respiratory and other infections. Most *Mycoplasma* infections never have a microbiological diagnosis because rapid, sensitive and specific methods for its direct detection are not readily available in physician offices or hospital laboratories.

Significant limitations continue to surround the accurate and reliable serological diagnosis of *M. pneumoniae* infection. These include the wide variation of the methods and diagnostic criteria used across studies, which results in the subsequent emergence of data that remain incomparable and often controversial because of discordant and, at times, incorrect methodologies used.

Numerous in-house PCR assays to detect *M. pneumoniae* have been developed. Proper validation and standardization are still often lacking, and quality control studies have revealed frequent deficiencies resulting in both false-negative and false positive results [34,37]. Consequently, ~~as in 2003,~~ all newly developed tests must be submitted to extensive validation before their introduction in the molecular diagnostic laboratory. Validation must be performed at several levels, including sample preparation, amplification, and detection. Since respiratory samples often contain substances inhibiting amplification, special attention should be paid to the efficiency of the reaction with these samples. Once a test is validated, it should be further evaluated in proficiency testing programs. Whereas quality control is an essential part of quality assurance in molecular diagnostics, proficiency panels for the detection of *M. pneumoniae* are not readily available. They are urgently needed to allow meaningful comparisons between the results obtained in different laboratories.

In conclusion, the following standards should be followed by all laboratories when validating new tests for the detection of *M. pneumoniae*: (i) having the ability to apply a 2nd PCR at another target to at least some cases in epidemic situations, (ii) performing

- Formatted: English (U.S.)
- Formatted: English (U.S.)
- Formatted: Superscript
- Formatted: English (U.S.)
- Formatted: English (U.S.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

proficiency testing regularly in a blind fashion to ensure proper test and personnel performance, and (iii) incorporating hierarchical acceptance criteria monitoring for test failures, including positive and negative controls, re-evaluating multiple consecutive positive specimens, and confirming that positive specimens were collected from persons meeting the clinical case definition. Furthermore, multicenter studies that use a large and geographically diverse repertoire of clinical specimens and compare data from >2 centers independently are likely to provide important insights into the performance of new assays

410

415

Given the high sensitivity and specificity of NAATs, NAATs are the preferred diagnostic procedures for the diagnosis of *M. pneumoniae* infections, provided that the quality of the procedures is controlled. Additional prospective multicenter studies on large numbers of patients with respiratory signs and symptoms, including hospitalized and non-hospitalized patients, are necessary to extend our knowledge on the epidemiology of *M.*

420

pneumoniae.

~~It is critically important for current and future investigators to recognize the urgent need for the adoption of a more unified and consistent diagnostic approach. a common set of recommendations should be developed.~~

Acknowledgments

425

Katherine Loens is supported through Priority 1 (Life Sciences, Genomics and Biotechnology for Health) of European Union's FP6, Contract number: LSHM-CT-2005-518226, GRACE.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 1 Summary of studies of respiratory infections due to *M. ~~yeoplasma~~ pneumoniae* in adults, published since 2003

Reference	Location	Subject age (years)	No of subjects tested	Diagnostic method(s)	No (%) of subjects infected with <i>M. pneumoniae</i>	Comments	Methodological problem(-s) ^a
[72] 2004	The Netherlands	1-88	159	P1 gene-based PCR, particle agglutination and ELISA	19 (11.9)	7 PCR positive, all also positive in at least 1 serological test, 2-fold titer increase in IgG was defined as positive	D
[58] 2004	Trinidad and Tobago	>2	132	IgM and IgG EIA on acute phase serum	88 (66.7)	36/88 IgM positive	B
[15] 2005	France	≥18	3198	P1-based PCR, Ag-detection by EIA	109 (3.6)	114 PCR positive, Ag-detection test had very low sensitivity and results were not mentioned as such.	E
[44] 2005	Chile	60-96	84	P1 gene-based PCR, 16S rRNA gene-based PCR, IgM and IgG indirect IF	11 (13.1)	8 positive by IFI (of which 4 by IFI alone), 7 PCR positive (of which 3 only by PCR),	...
[63] 2005	The Netherlands	≥18	107	PCR	0	PCR not described	A
[4] 2006	UK	≥18	80 patients 49 controls	P1- gene -based PCR, 16S rRNA-based PCR	1 (1.3)	1 PCR positive patient	...
[80] 2006	Denmark	18-96	235 patients 113 controls	P1 gene -based PCR and CFT	14 (5.5)	13 positive patients, 1 positive control Proportion of positive results by each test not specified	...
[73] 2007	India	≥18	100	Culture, IgM ELISA, cold agglutination	31 (31)	31 positive by culture, 21 positive by IgM ELISA, 34 positive by	...

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

				test on acute phase sera		cold agglutination test	
[36] 2008	Belgium	≥18	147	Mono and MX real-time NASBA, real-time PCR, culture, IgM and IgG EIA	19 (12.9)	8 positive by culture, 15 positive by PCR, 19 positive by real-time MX NASBA, 23 by mono real-time NASBA	...
[86] 2008	The Netherlands	≥18	201	PCR, CFT	8 (4.0)	7 positive by PCR, 8 positive by serology	A
[49] 2008	Japan	16->80	NS	Culture, IgM and IgG serology	210	PCR not specified 210 IgG <i>M. pneumoniae</i> positive, 38 culture positive	...

^a A: no information provided about the PCR and/or serological assay used; B: single IgG titer used as part of the criteria used to define an acute infection; C: EIA used as the only serodiagnostic tool; D: serological titers vary from those recommended for diagnosis of acute infections; E : 1 PCR assay used as the only diagnostic tool; F : (single) IgM titer used as the only serodiagnostic tool in some or all patients

Ag: antigen; CFT: complement fixation test; IFI: indirect immunofluorescence; IgA/G/M: Immunoglobulin A/G/M; MX: multiplex; NASBA: nucleic acid sequence-based amplification; ...: no major methodological problems identified

Table 2. Summary of studies of respiratory infections due to *Mycoplasma pneumoniae* in pediatric patients, published since 2003.

Reference	Location	Subject age (years)	No of subjects tested	Diagnostic method(s)	No (%) of subjects infected with <i>M. pneumoniae</i>	Comments	Methodological problem (s) ^a
[23] 2003	Chile	0-14	106	16S rRNA gene-based PCR, IgM serology (2 tests) on acute serum, culture	31 (29.2)	31 positive by IgM, in 28/31 cases serology was confirmed by PCR, 19 positive by culture	...
[19] 2004	The Netherlands	0-16	168	P1 gene-based PCR	4 (2.4)		E
[43] 2004	Greece	0.5-14	65	P1 gene-based PCR and IgM serology on acute phase serum	18 (27.5)	18 positive by IgM, 9 PCR positive	F
[51] 2004	Japan	0-14	369	16S rRNA gene-based PCR, CFT, culture	69 (18.7)	68 positive by PCR, 53 culture positive, 76 serology positive	...
[8] 2005	Finland	0.3-16	101	CFT, IgM and IgA serology	27 (27)	27 patients positive with 2 or more tests, 12 patients positive with only 1 test	C
[32] 2005	China	0-5	85 patients 185 controls	ATPase-based PCR	6 (7.1)	All positive results were found in patients	E
[75] 2005	India		93	IgM ELISA on acute phase serum	22 (24)	All positive by single IgM determination	F
[27] 2006	Finland	0-16	220	2 IgM EIAs	11 (5)	Not clear whether positive in acute, convalescent or both sera	F
[96] 2006	Japan	0-6	339	P1 gene-based PCR, passive agglutination, IgM,	81 (23.9)	66 PCR positive, 106 PA titers above 1:40, among PCR positive patients, 30/36 had a ≥ 4 -fold	...

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

					IgG, and IgA ELISA			increase in PA titer, 36/81 positive for IgG, 16/81 positive for IgA, and 54/81 positive for IgM
[65]	2007	Japan	0-15	194	Culture, CFT, rapid test	45 (23.2)		14 culture positive, ImmunoCard positive in 39 paired sera and in 14 acute sera, CFT results not mentioned
[76]	2007	Turkey	5-15	284	PCR, IgM ELISA on acute phase serum	NS		33/203 PCR positive, 86/284 IgM patients, only in 13 cases positive by both PCR and IgM
[64]	2008	Japan	0-15	73	16S rRNA gene based PCR, IgM and IgG serology	6 (8.2)		6/6 PCR positive, 5/6 IgG seroconversion/significant rise, 1 additional positive by IgG serology, 2/6 Immunocard assay positive, 12 additional patients positive by Immunocard assay

^a A: no information provided about the PCR and/or serological assay used; B: single IgG titer used as part of the criteria used to define an acute infection; C: EIA used as the only serodiagnostic tool; D: serological titers vary from those recommended for diagnosis of acute infections; E : 1 PCR assay used as the only diagnostic tool; F : (single) IgM titer used as the only serodiagnostic tool in some or all patients
 Ag: antigen; CFT: complement fixation test; IFI: indirect immunofluorescence; IgA/G/M: Immunoglobulin A/G/M; MX: multiplex; NASBA: nucleic acid sequence-based amplification; NS: not specified; ...: no major methodological problems identified

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 3. Summary of recent mono PCR assays for detection of *Mycoplasma pneumoniae*, published since 2003, and previously validated assays used as comparators.

Assay (ref)	year	Assay type	Detection format	Gene—Target (product sizebp)	PCR assay used as comparator for new assay	Non-PCR comparator test	Specimens tested for validation of sensitivity and or specificity
2003 [83]		PCR	Molecular beacons	P1 gene (151)	[21,39]	Serology	Various bacterial species, DNA dilutions, clinical specimens
2004 [51]		PCR	Agarose gel electrophoresis	16S rRNA gene (225)	---ND	Culture, serology	<i>M. pneumoniae</i> dilution series
2004 [70][69]		Broad range PCR	microarray	parE gene (±300)	---ND	---ND	Various bacterial species, DNA dilutions, clinical specimens
2004 [90]		Nested PCR	Reverse Line Blot Hybridization	16S-23S rRNA spacer (94)	---ND	---ND	21 mollicute reference strains, 92 contaminated cell cultures, 80 mollicute isolates, 14 <i>M. pneumoniae</i> positive NPAs, 6 <i>M. pneumoniae</i> negative specimens. Pathogens targeted: <i>Mycoplasma arginini</i> , <i>Mycoplasma fermentans</i> , <i>Mycoplasma hyorhinitis</i> , <i>Mycoplasma orale</i> , <i>Acholeplasma laidlawii</i> , <i>M. pneumoniae</i> , <i>Mycoplasma hominis</i> , <i>Mycoplasma genitalium</i> , <i>Ureaplasma parvum</i> , <i>Ureaplasma urealyticum</i> .
2005 [69]		PCR	Real-time	16S RNA-gene (NS)	---ND	Culture	Spiked sputa and BALs, clinical specimens with known <i>M. pneumoniae</i> status by culture
2005 [71]		LAMP	Turbidimeter	P1 gene (NS)	[84]	---ND	Various bacterial species, DNA dilutions, clinical specimens
2006 [54]		PCR	Molecular beacon	16S rRNA gene (225)	---ND	Culture, serology	Various bacterial species, bacterial dilution series, clinical specimens
2006 [68]		PCR	Real-time	P1 gene (141)	---ND	Culture, serology	Various bacterial strains, dilutions of cloned DNA, clinical specimens with known <i>M. pneumoniae</i>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

2007 [7]	PCR	Scorpion probe	P1_gene (72)	[24,74]	Serology	status by culture and serology Various bacterial strains, dilutions of <i>M. pneumoniae</i> DNA, clinical specimens with unknown status
2007 [12]	PCR	Real-time	repMp1 in P1 (184)	P1 gene based PCR (177bp)	--- ND	Various bacterial species, dilutions of plasmids containing target sequence, clinical specimens with known <i>M. pneumoniae</i> status by PCR
2008 [78]	Broad range PCR	Real-time	<i>Tuf</i> gene (160)	VenorGeM-DI Mycoplasma detection kit, MycoSensor QPCR Assay kit	--- ND	32 Mollicute species, various other bacterial species, cell culture supernatants, clinical specimens (80 sputa, 5 throat swabs). Specific <i>M. pneumoniae</i> detection obtained however, the MycoSensor QPCR assay does never detect <i>M. pneumoniae</i> whereas the VenorGeM-DI Mycoplasma detection kit gave inconclusive results
2008 [94]	PCR	Real-time	CARDS toxin gene (73) ATPase gene (68) ATPase gene (106)	--- ND	--- ND	Various bacterial species, bacterial dilution series, clinical specimens from an outbreak
<p>A-test: passive agglutination-test; LAMP: Loop-mediated isothermal amplification; ND: not done; MycoSensor QPCR Assay (Stratagene, La Jolla, USA); VenorGeM-DI Mycoplasma detection kit, (Minerva Biolabs, <u>GmbH</u>, Berlin, Germany);</p>						


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 4. Summary of recent multiplex PCR assays for detection of *Mycoplasma pneumoniae*, published since 2003, and previously validated assays used as comparators.

Assay (ref)	year	Assay type	Detection format	Target Gene (product sizebp)	PCR assay used as comparator for new assay	Non-PCR comparator test	Specimens tested for validation of sensitivity and or specificity
2004 [50]		MX PCR	Microchip electrophoresis	16S rRNA gene (88)	Mono-assay	Serology	<i>M. pneumoniae</i> dilution series, various bacterial species, clinical specimens Pathogens targeted: <i>M. pneumoniae</i> , <i>Chlamydia pneumoniae</i> , and <i>Legionella pneumophila</i>
2005 [3]		Mass Tag MX-PCR	Masscode Tag	NS	ND	ND	DNA dilutions, <i>M. pneumoniae</i> negative clinical specimens Pathogens targeted: influenza A and B, RSV A and B, metapneumovirus, SARS, coronavirus OC43 and 229E, parainfluenza 1-3, <i>C. pneumoniae</i> , <i>M. pneumoniae</i> , <i>L. pneumophila</i> , enterovirus, adenovirus
2005 [18]		MX-PCR Chlamylege	Hybridization	P1 gene (298)	[6]	Serology	Various bacterial species, bacterial dilutions, clinical specimens with known status, clinical specimens with unknown status Pathogens targeted: <i>C. pneumoniae</i> , <i>M. pneumoniae</i> , <i>Legionella</i> spp.
2005 [22]		MX-PCR Pneumoplex	Real-time	16S rRNA gene	NS	ND	Various bacterial species, dilutions of recombinant DNA, dilutions of organisms, spiked BALs Pathogens targeted: <i>M. pneumoniae</i> , <i>C. pneumoniae</i> , <i>L. pneumophila</i> , <i>Legionella micdadei</i> , <i>Bordetella pertussis</i>
2005 [46]		MX-PCR	Agarose gel electrophoresis	P1 gene (360)	[21]	ND	Various bacterial specimens, dilutions of organisms, clinical specimens with known <i>M. pneumoniae</i>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

2005 [79]	MX-PCR	Agarose gel electrophoresis	P1 gene (483)	---	ND	---	ND	status by PCR Pathogens targeted: <i>M. pneumoniae</i> , <i>C. pneumoniae</i> , <i>L. pneumophila</i> , <i>B. pertussis</i> Various bacterial species, serial dilutions of DNA, clinical respiratory specimens
2007 [17]	MX-PCR	Agarose gel electrophoresis	P1 gene (225)	---	NS	---	ND	Pathogens targeted: <i>S-treptococcus pneumoniae</i> , <i>H-aemophilus influenzae</i> , <i>M. pneumoniae</i> , and <i>C. pneumoniae</i> Extracts from samples known to be positive for some common respiratory bacterial pathogens, clinical specimens from children with RTIs Pathogens targeted: <i>M. pneumoniae</i> , <i>C. pneumoniae</i> , <i>B. pertussis</i> , <i>B-ordetella parapertussis</i>
2007 [26]	Nested MX-PCR	Agarose gel electrophoresis	P1 gene (343, 160)	---	NS	---	ND	DNA dilutions, clinical specimens Pathogens targeted: <i>M. pneumoniae</i> , <i>C. pneumoniae</i> , <i>L. pneumophila</i> , adenovirus
2007 [30]	MX-PCR	Resequencing microarray	---	NS	---	---	ND	Various bacterial species, <i>M. pneumoniae</i> cells, DNA dilutions, archived throat swabs Pathogens targeted: adenovirus, <i>B-acillus anthracis</i> , <i>C. pneumoniae</i> , influenza virus A and B, <i>Fransiscella- tularensis</i> , coronavirus 229 E and OC43, rhinovirus, Lassa virus, <i>M. pneumoniae</i> , parainfluenzavirus 1, 3, RSV A and B, <i>S. pneumoniae</i> , <i>S-treptococcus pyogenes</i> , vaccinia virus, <i>Y-ersinia pestis</i> , Ebola virus, and Variola major virus
2007 [33]	MX-PCR	Microarray with electrochemical detection	dnaK gene (654) pdhA gene (284) tuf gene (604)	---	NS	---	ND	Various bacterial and viral species, dilution series The pdhA primers and probes were found to be the most sensitive combination. Pathogens targeted: <i>B. pertussis</i> , <i>S. pyogenes</i> , <i>C. pneumoniae</i> , <i>M. pneumoniae</i> , adenovirus,



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49


2008 [2]	MX-PCR ResPlex	Luminex technology	ATPase (NS)	NS	--- ND	coronavirus OC43, 229E and HK, influenza A A and B, parainfluenza types 1, 2, and 3, RSV <i>M. pneumoniae</i> type I and II , >110 strains of other bacterial species found in the respiratory tract or related spp., 10-fold serial DNA dilutions, 49 NPS with known <i>M. pneumoniae</i> status by PCR. Pathogens targeted: <i>S. pneumoniae</i> , N-e <i>isseria meningitidis</i> , <i>H. influenzae</i> , <i>L. pneumophila</i> , <i>M. pneumoniae</i> , <i>C. pneumoniae</i> .
2008 [20]	MX-PCR	Molecular beacons	P1 gene (158)	[88]	--- ND	Reference strains of common bacterial respiratory pathogens or related species, serial dilutions of DNA, spiked samples, samples with known status by PCR Pathogens targeted: <i>M. pneumoniae</i> and <i>C. pneumoniae</i>
2008 [35]	MX NASBA	Molecular beacons	16S rRNA	[21,39]	Culture, serology	Various bacterial species, bacterial dilutions, dilutions of wild-type <i>M. pneumoniae</i> 16S rRNA generated in vitro, spiked specimens, specimens with known status by PCR Pathogens targeted: <i>M. pneumoniae</i> , <i>C. pneumoniae</i> , <i>Legionella</i> spp.
2008 [91]	MX-PCR	Reverse Line Blot Hybridization	16S-23S rRNA spacer (93)	[90]	--- ND	12 reference strains and 63 clinical isolates of common bacterial respiratory pathogens, 10-fold serial DNA dilutions, 100 NPAs from children with CAP Pathogens targeted: S-t <i>aphylococcus aureus</i> , <i>S. pneumoniae</i> , <i>S. pyogenes</i> , M-or <i>axella catarrhalis</i> , <i>H. influenzae</i> , <i>B. pertussis</i> , K-l <i>ebsiella pneumoniae</i> , <i>L. pneumophila</i> , M-y <i>cobacterium tuberculosis</i> , <i>C. pneumoniae</i> , <i>M. pneumoniae</i> .
2008 [25]	MX-PCR	Enzyme hybridization or	P1 gene(299)	--- ND	--- ND	Various bacterial and viral species, bacterial dilutions, spiked clinical specimens, clinical

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

electronic
microarray
detection

specimens from carriage study, reanalysis of samples with discrepant results
Pathogens targeted: influenza virus A, influenza virus B, RSV A and B, *M. pneumoniae*, *C. pneumoniae*, *L. pneumophila*, *L. micdadei*, *B. pertussis*, *S. aureus*, and *S. pneumoniae*.

A-test: passive agglutination-test; MX-PCR: multiplex PCR; NASBA: Nucleic acid sequence-based amplification; NPA: nasopharyngeal aspirate; NS: not specified; Pneumoplex, (~~Prodesse/GenProbe~~ Prodesse Inc., Waukesha, ~~Wisconsin~~USA); ResPlex; Qiagen (GmbH, Valencia, ~~CA~~, USA); M. pneumoniae OligoDetect PCR kit, (Millipore/Chemicon, Eugene, USA)



1
2
3
4
5 Reference List
6
7

- 8 1. Beersma MF, Dirven K, van Dam AP, Templeton KE, Claas EC, Goossens H
9 (2005) Evaluation of 12 commercial tests and the complement fixation test for
10 *Mycoplasma pneumoniae*-specific immunoglobulin G (IgG) and IgM
11 antibodies, with PCR used as the "gold standard". J.Clin.Microbiol., 43:2277-
12 2285.
- 13 2. Benson R, Tondella ML, Bhatnagar J, Carvalho MG, Sampson JS, Talkington
14 DF, Whitney AM, Mothershed E, McGee L, Carlone G, McClee V, Guarner J,
15 Zaki S, Dejsiri S, Cronin K, Han J, Fields BS (2008) Development and
16 evaluation of a novel multiplex PCR technology for molecular differential
17 detection of bacterial respiratory disease pathogens. J.Clin.Microbiol.,
18 46:2074-2077.
- 19 3. Briese T, Palacios G, Kokoris M, Jabado O, Liu Z, Renwick N, Kapoor V,
20 Casas I, Pozo F, Limberger R, Perez-Brena P, Ju J, Lipkin WI (2005)
21 Diagnostic system for rapid and sensitive differential detection of pathogens.
22 Emerg.Infect.Dis., 11:310-313.
- 23 4. Creer DD, Dilworth JP, Gillespie SH, Johnston AR, Johnston SL, Ling C,
24 Patel S, Sanderson G, Wallace PG, McHugh TD (2006) Aetiological role of
25 viral and bacterial infections in acute adult lower respiratory tract infection
26 (LRTI) in primary care. Thorax, 61:75-79.
- 27 5. Csango PA, Pedersen JE, Hess RD (2004) Comparison of four *Mycoplasma*
28 *pneumoniae* IgM-, IgG- and IgA-specific enzyme immunoassays in blood
29 donors and patients. Clin.Microbiol.Infect., 10:1094-1098.
- 30 6. de Barbeyrac B., Bernet-Poggi C, Febrer F, Renaudin H, Dupon M, Bebear C
31 (1993) Detection of *Mycoplasma pneumoniae* and *Mycoplasma genitalium* in
32 clinical samples by polymerase chain reaction. Clin.Infect.Dis., 17 Suppl
33 1:S83-S89.
- 34 7. Di Marco E., Cangemi G, Filippetti M, Melioli G, Biassoni R (2007)
35 Development and clinical validation of a real-time PCR using a uni-molecular
36 Scorpion-based probe for the detection of *Mycoplasma pneumoniae* in clinical
37 isolates. New Microbiol., 30:415-421.
- 38 8. Don M, Fasoli L, Paldanius M, Vainionpaa R, Kleemola M, Raty R, Leinonen
39 M, Korppi M, Tenore A, Canciani M (2005) Aetiology of community-
40 acquired pneumonia: serological results of a paediatric survey.
41 Scand.J.Infect.Dis., 37:806-812.
- 42 9. Dorigo-Zetsma JW, Zaat SA, Wertheim-van Dillen PM, Spanjaard L, Rijntjes
43 J, van Waveren G., Jensen JS, Angulo AF, Dankert J (1999) Comparison of
44 PCR, culture, and serological tests for diagnosis of *Mycoplasma pneumoniae*
45 respiratory tract infection in children. J.Clin.Microbiol., 37:14-17.
- 46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

10. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, Hammerschlag MR, Jackson LA, Kuo CC, Maass M, Messmer TO, Talkington DF, Tondella ML, Zaki SR (2001) Standardizing *Chlamydia pneumoniae* assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). *Clin.Infect.Dis.*, 33:492-503.
11. Dumke R, Jacobs E (2008) Comparison of commercial and in-house real-time PCR assays to detect *Mycoplasma pneumoniae*. *J.Clin.Microbiol.*
12. Dumke R, Schurwanz N, Lenz M, Schuppler M, Luck C, Jacobs E (2007) Sensitive detection of *Mycoplasma pneumoniae* in human respiratory tract samples by optimized real-time PCR approach. *J.Clin.Microbiol.*, 45:2726-2730.
13. Edward D.G.F. (1947) A selective medium for pleuropneumonia-like organisms. *J.Gen.Microbiol.*, 1:238-243.
14. Foy HM (1993) Infections caused by *Mycoplasma pneumoniae* and possible carrier state in different populations of patients. *Clin.Infect.Dis.*, 17 Suppl 1:S37-S46.
15. Gaillat J, Flahault A, deBarbeyrac B, Orfila J, Portier H, Ducroix JP, Bebear C, Mayaud C (2005) Community epidemiology of *Chlamydia* and *Mycoplasma pneumoniae* in LRTI in France over 29 months. *Eur.J.Epidemiol.*, 20:643-651.
16. Gavranich JB, Chang AB (2005) Antibiotics for community acquired lower respiratory tract infections (LRTI) secondary to *Mycoplasma pneumoniae* in children. *Cochrane.Database.Syst.Rev.*, CD004875.
17. Geertsen R, Kaeppli F, Sterk-Kuzmanovic N, Andrasevic S, nic-Milic T, Dobec M (2007) A multiplex PCR assay for the detection of respiratory bacteria in nasopharyngeal smears from children with acute respiratory disease. *Scand.J.Infect.Dis.*, 39:769-774.
18. Ginevra C, Barranger C, Ros A, Mory O, Stephan JL, Freymuth F, Joannes M, Pozzetto B, Grattard F (2005) Development and evaluation of Chlamylege, a new commercial test allowing simultaneous detection and identification of *Legionella*, *Chlamydophila pneumoniae*, and *Mycoplasma pneumoniae* in clinical respiratory specimens by multiplex PCR. *J.Clin.Microbiol.*, 43:3247-3254.
19. Gruteke P, Glas AS, Dierdorff M, Vreede WB, Pilon JW, Bruisten SM (2004) Practical implementation of a multiplex PCR for acute respiratory tract infections in children. *J.Clin.Microbiol.*, 42:5596-5603.
20. Gullsby K, Storm M, Bondeson K (2008) Simultaneous detection of *Chlamydophila pneumoniae* and *Mycoplasma pneumoniae* by use of molecular beacons in a duplex real-time PCR. *J.Clin.Microbiol.*, 46:727-731.

- 1
- 2
- 3
- 4 21. Ieven M, Ursi D, Van Bever H., Quint W, Niesters HG, Goossens H (1996)
- 5 Detection of *Mycoplasma pneumoniae* by two polymerase chain reactions and
- 6 role of *M. pneumoniae* in acute respiratory tract infections in pediatric
- 7 patients. J.Infect.Dis., 173:1445-1452.
- 8
- 9 22. Khanna M, Fan J, Pehler-Harrington K, Waters C, Douglass P, Stallock J,
- 10 Kehl S, Henrickson KJ (2005) The pneumoplex assays, a multiplex PCR-
- 11 enzyme hybridization assay that allows simultaneous detection of five
- 12 organisms, *Mycoplasma pneumoniae*, *Chlamydia (Chlamydophila)*
- 13 *pneumoniae*, *Legionella pneumophila*, *Legionella micdadei*, and *Bordetella*
- 14 *pertussis*, and its real-time counterpart. J.Clin.Microbiol., 43:565-571.
- 15
- 16 23. Kogan R, Martinez MA, Rubilar L, Paya E, Quevedo I, Puppo H, Girardi G,
- 17 Castro-Rodriguez JA (2003) Comparative randomized trial of azithromycin
- 18 versus erythromycin and amoxicillin for treatment of community-acquired
- 19 pneumonia in children. Pediatr.Pulmonol., 35:91-98.
- 20
- 21 24. Kong F, Gordon S, Gilbert GL (2000) Rapid-cycle PCR for detection and
- 22 typing of *Mycoplasma pneumoniae* in clinical specimens. J.Clin.Microbiol.,
- 23 38:4256-4259.
- 24
- 25 25. Kumar S, Wang L, Fan J, Kraft A, Bose ME, Tiwari S, Van DM, Haigis R,
- 26 Luo T, Ghosh M, Tang H, Haghnia M, Mather EL, Weisburg WG, Henrickson
- 27 KJ (2008) Detection of 11 common viral and bacterial pathogens causing
- 28 community-acquired pneumonia or sepsis in asymptomatic patients by using a
- 29 multiplex reverse transcription-PCR assay with manual (enzyme
- 30 hybridization) or automated (electronic microarray) detection.
- 31 J.Clin.Microbiol., 46:3063-3072.
- 32
- 33 26. Lam WY, Yeung AC, Tang JW, Ip M, Chan EW, Hui M, Chan PK (2007)
- 34 Rapid multiplex nested PCR for detection of respiratory viruses.
- 35 J.Clin.Microbiol., 45:3631-3640.
- 36
- 37 27. Lehtinen P, Jartti T, Virkki R, Vuorinen T, Leinonen M, Peltola V, Ruohola
- 38 A, Ruuskanen O (2006) Bacterial coinfections in children with viral wheezing.
- 39 Eur.J.Clin.Microbiol.Infect.Dis., 25:463-469.
- 40
- 41 28. Lieberman D, Lieberman D, Ben-Yaakov M, Shmarkov O, Gelfer Y,
- 42 Varshavsky R, Ohana B, Lazarovich Z, Boldur I (2002) Serological evidence
- 43 of *Mycoplasma pneumoniae* infection in acute exacerbation of COPD.
- 44 Diagn.Microbiol.Infect.Dis., 44:1-6.
- 45
- 46 29. Lieberman D, Lieberman D, Korsonsky I, Ben-Yaakov M, Lazarovich Z,
- 47 Friedman MG, Dvoskin B, Leinonen M, Ohana B, Boldur I (2002) A
- 48 comparative study of the etiology of adult upper and lower respiratory tract
- 49 infections in the community. Diagn.Microbiol.Infect.Dis., 42:21-28.
- 50
- 51 30. Lin B, Blaney KM, Malanoski AP, Ligler AG, Schnur JM, Metzgar D, Russell
- 52 KL, Stenger DA (2007) Using a resequencing microarray as a multiple
- 53 respiratory pathogen detection assay. J.Clin.Microbiol., 45:443-452.
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

- 1
- 2
- 3
- 4 31. Liu FC, Chen PY, Huang FL, Tsai CR, Lee CY, Lin CF (2008) Do serological
- 5 tests provide adequate rapid diagnosis of *Mycoplasma pneumoniae* infection?
- 6 Jpn.J.Infect.Dis., 61:397-399.
- 7
- 8 32. Liu G, Talkington DF, Fields BS, Levine OS, Yang Y, Tondella ML (2005)
- 9 *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* in young children from
- 10 China with community-acquired pneumonia. Diagn.Microbiol.Infect.Dis.,
- 11 52:7-14.
- 12
- 13 33. Lodes MJ, Suciú D, Wilmoth JL, Ross M, Munro S, Dix K, Bernards K,
- 14 Stover AG, Quintana M, Iihoshi N, Lyon WJ, Danley DL, McShea A (2007)
- 15 Identification of upper respiratory tract pathogens using electrochemical
- 16 detection on an oligonucleotide microarray. PLoS.ONE., 2:e924.
- 17
- 18 34. Loens K, MacKay WG, Scott C, Goossens H, Wallace P., Ieven M (2010) A
- 19 multicenter pilot external quality assessment programme to assess the quality
- 20 of molecular detection of *Chlamydia pneumoniae* and *Mycoplasma*
- 21 *pneumoniae* . J.Microbiol.Methods, In press.
- 22
- 23 35. Loens K, Beck T, Ursi D, Overdijk M, Sillekens P, Goossens H, Ieven M
- 24 (2008) Development of real-time multiplex nucleic acid sequence-based
- 25 amplification for detection of *Mycoplasma pneumoniae*, *Chlamydia*
- 26 *pneumoniae*, and *Legionella* spp. in respiratory specimens. J.Clin.Microbiol.,
- 27 46:185-191.
- 28
- 29 36. Loens K, Beck T, Ursi D, Overdijk M, Sillekens P, Goossens H, Ieven M
- 30 (2008) Evaluation of different nucleic acid amplification techniques for the
- 31 detection of *M. pneumoniae*, *C. pneumoniae* and *Legionella* spp. in respiratory
- 32 specimens from patients with community-acquired pneumonia.
- 33 J.Microbiol.Methods, 73:257-262.
- 34
- 35 37. Loens K, Beck T, Ursi D, Pattyn S, Goossens H, Ieven M (2006) Two quality
- 36 control exercises involving nucleic acid amplification methods for detection of
- 37 *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* and carried out 2
- 38 years apart (in 2002 and 2004). J.Clin.Microbiol., 44:899-908.
- 39
- 40 38. Loens K, Bergs K, Ursi D, Goossens H, Ieven M (2007) Evaluation of
- 41 NucliSens easyMAG for automated nucleic acid extraction from various
- 42 clinical specimens. J.Clin.Microbiol., 45:421-425.
- 43
- 44 39. Loens K, Ieven M, Ursi D, Beck T, Overdijk M, Sillekens P, Goossens H
- 45 (2003) Detection of *Mycoplasma pneumoniae* by real-time nucleic acid
- 46 sequence-based amplification. J.Clin.Microbiol., 41:4448-4450.
- 47
- 48 40. Loens K, Ursi D, Goossens H, Ieven M (2003) Molecular diagnosis of
- 49 *Mycoplasma pneumoniae* respiratory tract infections. J.Clin.Microbiol.,
- 50 41:4915-4923.
- 51
- 52 41. Loens K, Ursi D, Goossens H, Ieven M (2008) Evaluation of the NucliSens
- 53 miniMAG RNA extraction and real-time NASBA applications for the
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65

- 1
2
3
4 detection of *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in
5 throat swabs. J.Microbiol.Methods, 72:217-219.
6
7 42. Loens K, Van HL, Malhotra-Kumar S, Goossens H, Ieven M (2009) Optimal
8 sampling sites and methods for detection of pathogens possibly causing
9 community-acquired lower respiratory tract infections. J.Clin.Microbiol.,
10 47:21-31.
11
12 43. Maltezou HC, La-Scola B, Astra H, Constantopoulou I, Vlahou V, Kafetzis
13 DA, Constantopoulos AG, Raoult D (2004) *Mycoplasma pneumoniae* and
14 *Legionella pneumophila* in community-acquired lower respiratory tract
15 infections among hospitalized children: diagnosis by real time PCR.
16 Scand.J.Infect.Dis., 36:639-642.
17
18 44. Martinez TM, Pino PY, Salazar BT, Jover LE, Caroca CC, Espinoza NM,
19 Avendano CL (2005) [Diagnostic utility of the polymerase chain reaction for
20 the diagnosis of *Mycoplasma pneumoniae* in elderly patients with community-
21 acquired pneumonia]. Rev.Chilena.Infectol., 22:251-256.
22
23 45. Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, Suzuki I,
24 Andoh T, Kenri T, Sasaki Y, Horino A, Shintani M, Arakawa Y, Sasaki T
25 (2004) Characterization and molecular analysis of macrolide-resistant
26 *Mycoplasma pneumoniae* clinical isolates obtained in Japan.
27 Antimicrob.Agents Chemother., 48:4624-4630.
28
29 46. McDonough EA, Barrozo CP, Russell KL, Metzgar D (2005) A multiplex
30 PCR for detection of *Mycoplasma pneumoniae*, *Chlamydia pneumoniae*,
31 *Legionella pneumophila*, and *Bordetella pertussis* in clinical specimens.
32 Mol.Cell Probes, 19:314-322.
33
34 47. Menendez R, Cordoba J, de La CP, Cremades MJ, Lopez-Hontagas JL,
35 Salavert M, Gobernado M (1999) Value of the polymerase chain reaction
36 assay in noninvasive respiratory samples for diagnosis of community-acquired
37 pneumonia. Am.J.Respir.Crit Care Med., 159:1868-1873.
38
39 48. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, Kauppila
40 J, Leinonen M, McCracken GH, Jr. (2004) Epidemiology and clinical
41 characteristics of community-acquired pneumonia in hospitalized children.
42 Pediatrics, 113:701-707.
43
44 49. Miyashita N, Ouchi K, Kawasaki K, Oda K, Kawai Y, Shimizu H, Kobashi Y,
45 Oka M (2008) *Mycoplasma pneumoniae* pneumonia in the elderly.
46 Med.Sci.Monit., 14:CR387-CR391.
47
48 50. Miyashita N, Saito A, Kohno S, Yamaguchi K, Watanabe A, Oda H,
49 Kazuyama Y, Matsushima T (2004) Multiplex PCR for the simultaneous
50 detection of *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Legionella*
51 *pneumophila* in community-acquired pneumonia. Respir.Med., 98:542-550.
52
53 51. Morozumi M, Hasegawa K, Chiba N, Iwata S, Kawamura N, Kuroki H,
54 Tajima T, Ubukata K (2004) Application of PCR for *Mycoplasma pneumoniae*

- 1
2
3
4 detection in children with community-acquired pneumonia.
5 J.Infect.Chemother., 10:274-279.
6
7 52. Morozumi M, Hasegawa K, Kobayashi R, Inoue N, Iwata S, Kuroki H,
8 Kawamura N, Nakayama E, Tajima T, Shimizu K, Ubukata K (2005)
9 Emergence of macrolide-resistant *Mycoplasma pneumoniae* with a 23S rRNA
10 gene mutation. Antimicrob.Agents Chemother., 49:2302-2306.
11
12 53. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K,
13 Nakayama E, Sunakawa K, Ubukata K (2008) Increased macrolide resistance
14 of *Mycoplasma pneumoniae* in pediatric patients with community-acquired
15 pneumonia. Antimicrob.Agents Chemother., 52:348-350.
16
17 54. Morozumi M, Nakayama E, Iwata S, Aoki Y, Hasegawa K, Kobayashi R,
18 Chiba N, Tajima T, Ubukata K (2006) Simultaneous detection of pathogens in
19 clinical samples from patients with community-acquired pneumonia by real-
20 time PCR with pathogen-specific molecular beacon probes. J.Clin.Microbiol.,
21 44:1440-1446.
22
23 55. MORTON HE, SMITH PF, LEBERMAN PR (1951) Investigation of the
24 cultivation of pleuropneumonia-like organisms from man.
25 Am.J.Syph.Gonorrhea.Vener.Dis., 35:361-369.
26
27 56. Mundy LM, Auwaerter PG, Oldach D, Warner ML, Burton A, Vance E,
28 Gaydos CA, Joseph JM, Gopalan R, Moore RD, . (1995) Community-acquired
29 pneumonia: impact of immune status. Am.J.Respir.Crit Care Med., 152:1309-
30 1315.
31
32 57. Murray PRE, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover
33 RH: *Manual of Clinical Microbiology.*, edn 8th. Washington DC: ASM Press; 2003.
34
35 58. Nagalingam NA, Adesiyun AA, Swanston WH, Bartholomew M (2004)
36 Prevalence of *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* in
37 pneumonia patients in four major hospitals in Trinidad. New Microbiol.,
38 27:345-351.
39
40 59. Narita M (2005) Evaluation of ELISA kits for detection of *Mycoplasma*
41 *pneumoniae* specific IgG, IgA and IgM antibodies on the diagnosis of *M.*
42 *pneumoniae* in children. The Journal of Japanese Association for Infectious
43 diseases, 79:457-463.
44
45 60. Nilsson AC, Bjorkman P, Persson K (2008) Polymerase chain reaction is
46 superior to serology for the diagnosis of acute *Mycoplasma pneumoniae*
47 infection and reveals a high rate of persistent infection. BMC.Microbiol., 8:93.
48
49 61. Nir-Paz R, Michael-Gayego A, Ron M, Block C (2006) Evaluation of eight
50 commercial tests for *Mycoplasma pneumoniae* antibodies in the absence of
51 acute infection. Clin.Microbiol.Infect., 12:685-688.
52
53 62. Okazaki N, Narita M, Yamada S, Izumikawa K, Umetsu M, Kenri T, Sasaki
54 Y, Arakawa Y, Sasaki T (2001) Characteristics of macrolide-resistant
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 *Mycoplasma pneumoniae* strains isolated from patients and induced with
5 erythromycin in vitro. *Microbiol.Immunol.*, 45:617-620.
6
7 63. Oosterheert JJ, van Loon AM, Schuurman R, Hoepelman AI, Hak E, Thijsen
8 S, Nossent G, Schneider MM, Hustinx WM, Bonten MJ (2005) Impact of
9 rapid detection of viral and atypical bacterial pathogens by real-time
10 polymerase chain reaction for patients with lower respiratory tract infection.
11 *Clin.Infect.Dis.*, 41:1438-1444.
12
13 64. Otomo S, Yamamura J, Hayashi E, Nakamura T, Kakinuma H, Nakamoto Y,
14 Takahashi H, Karasawa T (2008) Analysis of children with *Chlamydia*
15 (*Chlamydia*) *pneumoniae* and *Mycoplasma pneumoniae* respiratory infections
16 by real-time PCR assay and serological tests. *APMIS*, 116:477-483.
17
18 65. Ozaki T, Nishimura N, Ahn J, Watanabe N, Muto T, Saito A, Koyama N,
19 Nakane K, Funahashi K (2007) Utility of a rapid diagnosis kit for *Mycoplasma*
20 *pneumoniae* pneumonia in children, and the antimicrobial susceptibility of the
21 isolates. *J.Infect.Chemother.*, 13:204-207.
22
23 66. Pereyre S, Charron A, Renaudin H, Bebear C, Bebear CM (2007) First report
24 of macrolide-resistant strains and description of a novel nucleotide sequence
25 variation in the P1 adhesin gene in *Mycoplasma pneumoniae* clinical strains
26 isolated in France over 12 years. *J.Clin.Microbiol.*, 45:3534-3539.
27
28 67. Petitjean J, Vabret A, Gouarin S, Freymuth F (2002) Evaluation of four
29 commercial immunoglobulin G (IgG)- and IgM-specific enzyme
30 immunoassays for diagnosis of *Mycoplasma pneumoniae* infections.
31 *J.Clin.Microbiol.*, 40:165-171.
32
33 68. Pitcher D, Chalker VJ, Sheppard C, George RC, Harrison TG (2006) Real-
34 time detection of *Mycoplasma pneumoniae* in respiratory samples with an
35 internal processing control. *J.Med.Microbiol.*, 55:149-155.
36
37 69. Raggam RB, Leitner E, Berg J, Muhlbauer G, Marth E, Kessler HH (2005)
38 Single-run, parallel detection of DNA from three pneumonia-producing
39 bacteria by real-time polymerase chain reaction. *J.Mol.Diagn.*, 7:133-138.
40
41 70. Roth SB, Jalava J, Ruuskanen O, Ruohola A, Nikkari S (2004) Use of an
42 oligonucleotide array for laboratory diagnosis of bacteria responsible for acute
43 upper respiratory infections. *J.Clin.Microbiol.*, 42:4268-4274.
44
45 71. Saito R, Misawa Y, Moriya K, Koike K, Ubukata K, Okamura N (2005)
46 Development and evaluation of a loop-mediated isothermal amplification
47 assay for rapid detection of *Mycoplasma pneumoniae*. *J.Med.Microbiol.*,
48 54:1037-1041.
49
50 72. Schneeberger PM, Dorigo-Zetsma JW, van der ZA, van BM, van Opstal JL
51 (2004) Diagnosis of atypical pathogens in patients hospitalized with
52 community-acquired respiratory infection. *Scand.J.Infect.Dis.*, 36:269-273.
53
54
55
56
57
58
59
60
61
62
63
64
65


- 1
2
3
4 73. Shankar EM, Kumarasamy N, Balakrishnan P, Saravanan S, Solomon S,
5 Vengatesan A, Murugavel KG, Rao UA (2007) Detection of pulmonary
6 *Mycoplasma pneumoniae* infections in HIV-infected subjects using culture
7 and serology. *Int.J.Infect.Dis.*, 11:232-238.
8
9 74. Sharma S, Brousseau R, Kasatiya S (1998) Detection and confirmation of
10 *Mycoplasma pneumoniae* in urogenital specimens by PCR. *J.Clin.Microbiol.*,
11 36:277-280.
12
13 75. Shenoy VD, Upadhyaya SA, Rao SP, Shobha KL (2005) *Mycoplasma*
14 *pneumoniae* infection in children with acute respiratory infection.
15 *J.Trop.Pediatr.*, 51:232-235.
16
17 76. Sidal M, Kilic A, Unuvar E, Oguz F, Onel M, Agacfidan A, Aydin D,
18 Koksalan K, Beka H (2007) Frequency of *Chlamydia pneumoniae* and
19 *Mycoplasma pneumoniae* infections in children. *J.Trop.Pediatr.*, 53:225-231.
20
21 77. Skerrett SJ (1999) Diagnostic testing for community-acquired pneumonia.
22 *Clin.Chest Med.*, 20:531-548.
23
24 78. Stormer M, Vollmer T, Henrich B, Kleesiek K, Dreier J (2008) Broad-range
25 real-time PCR assay for the rapid identification of cell-line contaminants and
26 clinically important mollicute species. *Int.J.Med.Microbiol.*
27
28 79. Stralin K, Backman A, Holmberg H, Fredlund H, Olcen P (2005) Design of a
29 multiplex PCR for *Streptococcus pneumoniae*, *Haemophilus influenzae*,
30 *Mycoplasma pneumoniae* and *Chlamydia pneumoniae* to be used on
31 sputum samples. *APMIS*, 113:99-111.
32
33 80. Stralin K, Tornqvist E, Kaltoft MS, Olcen P, Holmberg H (2006) Etiologic
34 diagnosis of adult bacterial pneumonia by culture and PCR applied to
35 respiratory tract samples. *J.Clin.Microbiol.*, 44:643-645.
36
37 81. Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, Matsuoka
38 M, Kenri T, Arakawa Y, Sasaki T (2006) Clinical evaluation of macrolide-
39 resistant *Mycoplasma pneumoniae*. *Antimicrob.Agents Chemother.*, 50:709-
40 712.
41
42 82. Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL (2004)
43 Analysis of eight commercial enzyme immunoassay tests for detection of
44 antibodies to *Mycoplasma pneumoniae* in human serum. *Clin.Diagn.Lab*
45 *Immunol.*, 11:862-867.
46
47 83. Templeton KE, Scheltinga SA, Graffelman AW, Van Schie JM, Crielaard JW,
48 Sillekens P, van den Broek PJ, Goossens H, Beersma MF, Claas EC (2003)
49 Comparison and evaluation of real-time PCR, real-time nucleic acid sequence-
50 based amplification, conventional PCR, and serology for diagnosis of
51 *Mycoplasma pneumoniae*. *J.Clin.Microbiol.*, 41:4366-4371.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4 84. Ursi D, Dirven K, Loens K, Ieven M, Goossens H (2003) Detection of
5 *Mycoplasma pneumoniae* in respiratory samples by real-time PCR using an
6 inhibition control. J.Microbiol.Methods, 55:149-153.
7
8 85. Ursi D, Ieven M, Noordhoek GT, Ritzler M, Zandleven H, Altwegg M (2003)
9 An interlaboratory comparison for the detection of *Mycoplasma pneumoniae*
10 in respiratory samples by the polymerase chain reaction. J.Microbiol.Methods,
11 53:289-294.
12
13 86. van de Garde EM, Endeman H, van Hemert RN, Voorn GP, Deneer VH,
14 Leufkens HG, van den Bosch JM, Biesma DH (2008) Prior outpatient
15 antibiotic use as predictor for microbial aetiology of community-acquired
16 pneumonia: hospital-based study. Eur.J.Clin.Pharmacol., 64:405-410.
17
18 87. van Kuppeveld FJ, Johansson KE, Galama JM, Kissing J, Bolske G, Hjelm E,
19 van der Logt JT, Melchers WJ (1994) 16S rRNA based polymerase chain
20 reaction compared with culture and serological methods for diagnosis of
21 *Mycoplasma pneumoniae* infection. Eur.J.Clin.Microbiol.Infect.Dis., 13:401-
22 405.
23
24 88. van Kuppeveld FJ, van der Logt JT, Angulo AF, van Zoest MJ, Quint WG,
25 Niesters HG, Galama JM, Melchers WJ (1992) Genus- and species-specific
26 identification of mycoplasmas by 16S rRNA amplification.
27 Appl.Environ.Microbiol., 58:2606-2615.
28
29 89. Vikerfors T, Brodin G, Grandien M, Hirschberg L, Krook A, Pettersson CA
30 (1988) Detection of specific IgM antibodies for the diagnosis of *Mycoplasma*
31 *pneumoniae* infections: a clinical evaluation. Scand.J.Infect.Dis., 20:601-610.
32
33 90. Wang H, Kong F, Jelfs P, James G, Gilbert GL (2004) Simultaneous detection
34 and identification of common cell culture contaminant and pathogenic
35 mollicutes strains by reverse line blot hybridization. Appl.Environ.Microbiol.,
36 70:1483-1486.
37
38 91. Wang Y, Kong F, Yang Y, Gilbert GL (2008) A multiplex PCR-based reverse
39 line blot hybridization (mPCR/RLB) assay for detection of bacterial
40 respiratory pathogens in children with pneumonia. Pediatr.Pulmonol., 43:150-
41 159.
42
43 92. Waris ME, Toikka P, Saarinen T, Nikkari S, Meurman O, Vainionpaa R,
44 Mertsola J, Ruuskanen O (1998) Diagnosis of *Mycoplasma pneumoniae*
45 pneumonia in children. J.Clin.Microbiol., 36:3155-3159.
46
47 93. Watkins-Riedel T, Stanek G, Daxboeck F (2001) Comparison of SeroMP IgA
48 with four other commercial assays for serodiagnosis of *Mycoplasma*
49 *pneumoniae* pneumonia. Diagn.Microbiol.Infect.Dis., 40:21-25.
50
51 94. Winchell JM, Thurman KA, Mitchell SL, Thacker WL, Fields BS (2008)
52 Evaluation of three real-time PCR assays for detection of *Mycoplasma*
53 *pneumoniae* in an outbreak investigation. J.Clin.Microbiol., 46:3116-3118.
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

95. Wolff BJ, Thacker WL, Schwartz SB, Winchell JM (2008) Detection of macrolide resistance in *Mycoplasma pneumoniae* by real-time PCR and high-resolution melt analysis. *Antimicrob. Agents Chemother.*, 52:3542-3549.

96. Yamazaki T, Narita M, Sasaki N, Kenri T, Arakawa Y, Sasaki T (2006) Comparison of PCR for sputum samples obtained by induced cough and serological tests for diagnosis of *Mycoplasma pneumoniae* infection in children. *Clin. Vaccine Immunol.*, 13:708-710.



Electronic Supplementary Material

[Click here to download Electronic Supplementary Material: update minireview supplemental material 12032010.doc](#)